GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mountain Valley MD Holdings Inc (FRA:20MP) » Definitions » Debt-to-EBITDA

Mountain Valley MD Holdings (FRA:20MP) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Mountain Valley MD Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mountain Valley MD Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Mountain Valley MD Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Mountain Valley MD Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was €-2.40 Mil. Mountain Valley MD Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mountain Valley MD Holdings's Debt-to-EBITDA or its related term are showing as below:

FRA:20MP's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.695
* Ranked among companies with meaningful Debt-to-EBITDA only.

Mountain Valley MD Holdings Debt-to-EBITDA Historical Data

The historical data trend for Mountain Valley MD Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mountain Valley MD Holdings Debt-to-EBITDA Chart

Mountain Valley MD Holdings Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
-0.03 -0.01 -0.01 -

Mountain Valley MD Holdings Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mountain Valley MD Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mountain Valley MD Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mountain Valley MD Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mountain Valley MD Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mountain Valley MD Holdings's Debt-to-EBITDA falls into.



Mountain Valley MD Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mountain Valley MD Holdings's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.004 + 0) / -3.485
=-0.00

Mountain Valley MD Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -2.404
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Mountain Valley MD Holdings  (FRA:20MP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Mountain Valley MD Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mountain Valley MD Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mountain Valley MD Holdings (FRA:20MP) Business Description

Traded in Other Exchanges
Address
260 Edgeley Boulevard, Unit 4, Vaughan, ON, CAN, L6K 3Y4
Mountain Valley MD Holdings Inc is a Canada-based company. The firm along with its subsidiaries is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The Quicksome desiccation technology utilizes liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into efficient product formats that are consumed orally.

Mountain Valley MD Holdings (FRA:20MP) Headlines

No Headlines